Kevin Judice - 14 Sep 2021 Form 4 Insider Report for DICE Therapeutics, Inc.

Role
CEO, Director
Signature
/s/ Scott Robertson as attorney-in-fact for J. Kevin Judice
Issuer symbol
N/A
Transactions as of
14 Sep 2021
Net transactions value
$0
Form type
4
Filing time
16 Sep 2021, 21:18:02 UTC
Next filing
19 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DICE Common Stock 813,383 14 Sep 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DICE Stock Option (right to buy) Award $0 +20,464 $0.000000 20,464 14 Sep 2021 Common Stock 20,464 $17.00 Direct F3
transaction DICE Stock Option (right to buy) Award $0 +16,661 $0.000000 16,661 14 Sep 2021 Common Stock 16,661 $17.00 Direct F4
transaction DICE Stock Option (right to buy) Award $0 +131,027 $0.000000 131,027 14 Sep 2021 Common Stock 131,027 $17.00 Direct F5
transaction DICE Stock Option (right to buy) Award $0 +27,746 $0.000000 27,746 14 Sep 2021 Common Stock 27,746 $17.00 Direct F6
transaction DICE Stock Option (right to buy) Award $0 +15,497 $0.000000 15,497 14 Sep 2021 Common Stock 15,497 $17.00 Direct F6
transaction DICE Stock Option (right to buy) Award $0 +88,831 $0.000000 88,831 14 Sep 2021 Common Stock 88,831 $17.00 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares of Common Stock reported in the Reporting Holder's Form 3 reflected the conversion of derivative securities based on the midpoint of the Issuer's initial public offering range of $16.00 per share. The number of shares of Common Stock reflected in this Form 4 reflects the adjusted number of shares issued based on the higher initial public offering price of $17.00 per share, and does not reflect a disposition of shares.
F2 Certain of the shares are subject to the Issuer's right of repurchase if underlying vesting conditions are not met.
F3 The option is fully vested and exercisable.
F4 The option vests as to 1/48th of the total shares monthly, beginning October 2, 2018, subject to the Reporting Holder's continuing employment with the Registrant.
F5 The option vests as to 1/48th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continuing employment with the Registrant.
F6 The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continuing employment with the Registrant.